Relafen vs. Lamictal

Summary

We compare the side effects and drug effectiveness of Relafen and Lamictal. The study is created by eHealthMe based on reports of 113,902 people who take Relafen and Lamictal, and is updated regularly.



What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on nabumetone and lamotrigine (the active ingredients of Relafen and Lamictal, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. (latest outcomes from Relafen 5,722 users)

What is Lamictal?

Lamictal has active ingredients of lamotrigine. It is often used in bipolar disorder. (latest outcomes from Lamictal 64,115 users)

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Mar, 09, 2019

113,902 people who take Relafen and Lamictal are studied.


Number of reports submitted per year:

Relafen vs Lamictal drug comparison reports.

Drugs in this study:

  • Relafen (nabumetone)
  • Lamictal (lamotrigine)

Most common side effects:

Relafen:
  1. Rash
  2. Drug Ineffective
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  4. Pyrexia (fever)
  5. Nausea (feeling of having an urge to vomit)
  6. Headache (pain in head)
  7. Dizziness
  8. Fatigue (feeling of tiredness)
  9. Depression
  10. Vomiting
Lamictal:
  1. Nausea (feeling of having an urge to vomit)
  2. Drug Ineffective
  3. Dyspnoea (difficult or laboured respiration)
  4. Headache (pain in head)
  5. Anxiety
  6. Arthralgia (joint pain)
  7. Fatigue (feeling of tiredness)
  8. Diarrhoea
  9. Back Pain
  10. Depression

Most common side effects experienced by people in long term use:

Relafen:
  1. Rash
  2. Depression
  3. Drug Ineffective
  4. Anxiety
  5. Dizziness
  6. Fatigue (feeling of tiredness)
  7. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  8. Nausea (feeling of having an urge to vomit)
  9. Headache (pain in head)
  10. Insomnia (sleeplessness)
Lamictal:
  1. Gastrooesophageal Reflux Disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  2. Diarrhoea
  3. Depression
  4. Emotional Distress
  5. Nausea (feeling of having an urge to vomit)
  6. Hypertension (high blood pressure)
  7. Dyspepsia (indigestion)
  8. Anxiety
  9. Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  10. Anaemia (lack of blood)

Drug effectiveness:

Relafen:
  • not at all: 3.47 %
  • somewhat: 18.19 %
  • moderate: 30.76 %
  • high: 31.12 %
  • very high: 16.45 %
Lamictal:
  • not at all: 5.98 %
  • somewhat: 33.89 %
  • moderate: 35.55 %
  • high: 21.26 %
  • very high: 3.32 %

Do you take Relafen or Lamictal?

You are not alone:




Related publications that referenced our studies

Related studies:

Compare Relafen with similar drugs
Compare Lamictal with similar drugs


Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.